SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 4, 2020

 

BIOELIFE CORP.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

Nevada

  

333-144944

  

98-0514250

(State or other jurisdiction

  

(Commission File Number)

  

(IRS Employer

of Incorporation)

  

  

  

Identification Number)

  

  

  

  

  

  

  

12340 Seal Beach Blvd. Suite B-190

Seal Beach, CA 90740

  

  

  

  

(Address of principal executive offices)

  

  

  

  

(702) 866-2500

  

  

  

  

(Registrant’s Telephone Number)

  

  

U.S. Lithium Corp. 

(Former name or former address, if changed since last report)

 

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

          .    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

          .    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

          .    Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

          .    Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

1

Item 2.03 Creation of Direct Financial Obligation.

 

On March 4, 2020 U. S. Lithium Corp. (the “Company”) concluded a loan agreement (the “Agreement”) with Catanga International S.A. (CI), a company based in Belize. The Company issued to CI an unsecured, convertible promissory note for $100,000. The note is for a term of one year and bears interest at the rate of 10% per annum. At the election of the holder the note may be converted into common shares in the Company at a 30% discount to the then trading price of the Company’s stock.

 

The foregoing summary of the note issued by the Company to CI is qualified by reference to the full text of the agreement, which is filed as Exhibit 2.03 hereto and incorporated herein by reference.

 

 

 

Item 5.03 Amendment to Articles of Incorporation

 

Pursuant to the definitive information statement filed with the Commission on February 10, 2020, and pursuant to the approval of a majority of our shareholders and our board of directors, the Company amended its Articles of Incorporation on March 3, 2020, changing its name from U.S. Lithium Corp. to BioELife Corp. This change was effective March 3, 2020 as reflected in the Certificate of Amendment with the State of Nevada, a copy of which is attached hereto as Exhibit 5.03 and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit
Number

 

Exhibit Description

 

 

 

2.03

 

Unsecured Convertible Promissory Note issued to Catanga International S.A.

 5.03

 

Certificate of Amendment to Articles of Incorporation.

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

Date: March 6, 2020

U.S. Lithium Corp.

  

  

  

By:  /s/ Gregory Rotelli

 

  

Gregory Rotelli

  

 

President & CEO

 

 

Other Events.

 

US Lithium (CE) (USOTC:LITH)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas US Lithium (CE).
US Lithium (CE) (USOTC:LITH)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas US Lithium (CE).